Novartis Hopes Lubris In-Licensing Deal Will Lead To Dry Eye Solution

ON the lookout for potential ophthalmology options despite recent setbacks in the area, Novartis has now spotted ECF843, an investigative recombinant human lubricin – or natural lubricant – for dry eye.

Climate change

Continuing its search for ophthalmic drivers, Novartis AG has in-licensed a recombinant human lubricin from Lµbris BioPharma which it hopes will become a solution for dry eye, a condition with high unmet medical need that affects more than 344 million patients globally.

The in-licensing arrangement for the product, dubbed ECF843, was announced April 6 and gives the Swiss drug maker commercial rights...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip